share_log

Vertex Pharmaceuticals | 8-K: Current report

Vertex Pharmaceuticals | 8-K: Current report

福泰製藥 | 8-K:重大事件
美股sec公告 ·  05/20 08:40
Moomoo AI 已提取核心訊息
On May 20, 2024, Vertex Pharmaceuticals Incorporated, a Massachusetts-based biotechnology company, announced the successful completion of its acquisition of Alpine Immune Sciences, Inc., a Delaware corporation. The acquisition, valued at approximately $5.0 billion in equity, was finalized following an agreement that was initially reported on April 11, 2024. The transaction was executed through a merger with Vertex's wholly owned subsidiary, Adams Merger Sub, Inc., resulting in Alpine becoming a wholly owned subsidiary of Vertex. The accounting treatment for the acquisition is expected to be completed in the second quarter of 2024. This strategic move is part of Vertex's expansion plans and is subject to the usual risks and uncertainties associated with such forward-looking statements.
On May 20, 2024, Vertex Pharmaceuticals Incorporated, a Massachusetts-based biotechnology company, announced the successful completion of its acquisition of Alpine Immune Sciences, Inc., a Delaware corporation. The acquisition, valued at approximately $5.0 billion in equity, was finalized following an agreement that was initially reported on April 11, 2024. The transaction was executed through a merger with Vertex's wholly owned subsidiary, Adams Merger Sub, Inc., resulting in Alpine becoming a wholly owned subsidiary of Vertex. The accounting treatment for the acquisition is expected to be completed in the second quarter of 2024. This strategic move is part of Vertex's expansion plans and is subject to the usual risks and uncertainties associated with such forward-looking statements.
2024年5月20日,總部位於馬薩諸塞州的生物技術公司Vertex Pharmicals Incorporated宣佈成功完成對特拉華州公司Alpine Immune Sciences, Inc. 的收購。此次收購的股權價值約爲50億美元,是在最初於2024年4月11日公佈的協議後完成的。該交易是通過與Vertex的全資子公司Adams Merger Sub, Inc. 的合併執行的,這使阿爾派成爲Vertex的全資子公司。此次收購的會計處理預計將於2024年第二季度完成。這一戰略舉措是Vertex擴張計劃的一部分,受與此類前瞻性陳述相關的常見風險和不確定性的影響。
2024年5月20日,總部位於馬薩諸塞州的生物技術公司Vertex Pharmicals Incorporated宣佈成功完成對特拉華州公司Alpine Immune Sciences, Inc. 的收購。此次收購的股權價值約爲50億美元,是在最初於2024年4月11日公佈的協議後完成的。該交易是通過與Vertex的全資子公司Adams Merger Sub, Inc. 的合併執行的,這使阿爾派成爲Vertex的全資子公司。此次收購的會計處理預計將於2024年第二季度完成。這一戰略舉措是Vertex擴張計劃的一部分,受與此類前瞻性陳述相關的常見風險和不確定性的影響。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息